A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-19

Study Completion Date

2023-12-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate the safety and efficacy of 4 dose cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).

The objectives of this study were to evaluate the safety, tolerability, duration of effect, systemic pharmacokinetic and immunogenicity profiles of ascending doses of AG-73305 administered by intravitreal injection to patients with DME. Pharmacodynamic endpoints (e.g., best-corrected visual acuity \[BCVA\], spectral domain optical coherence tomography \[SD-OCT\], and optical coherence tomography angiography \[OCT-A\]) were evaluated over 6 months post-treatment. The maximum tolerated dose or the highest administered dose was evaluated for future studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

NCT01702441

Diabetic Macular Edema (DME)

COMPLETED PHASE1/PHASE2

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

NCT04697758

Diabetic Macular Edema (DME)

TERMINATED PHASE1/PHASE2

A Study of Avoralstat In Participants With Diabetic Macular Edema

NCT07228559

Diabetic Macular Edema (DME)

RECRUITING PHASE1

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923

Diabetes Mellitus Diabetic Retinopathy Diabetic Macular Edema

COMPLETED PHASE1

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

NCT01331681

Diabetes Mellitus Macular Edema

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

0.5 mg AG-73305 solution, single injection.

Group Type EXPERIMENTAL

AG-73305

Intervention Type BIOLOGICAL

drug product solution

Cohort 2

1 mg AG-73305 solution, single injection.

Group Type EXPERIMENTAL

AG-73305

Intervention Type BIOLOGICAL

drug product solution

Cohort 3

2 mg AG-73305 solution, single injection.

Group Type EXPERIMENTAL

AG-73305

Intervention Type BIOLOGICAL

drug product solution

Cohort 4

4 mg AG-73305 solution, single injection.

Group Type EXPERIMENTAL

AG-73305

Intervention Type BIOLOGICAL

drug product solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AG-73305

drug product solution

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, 18 years of age or older at the screening visit
2. Prior diagnosis of diabetes mellitus (Type 1 or Type 2) as defined by World Health Organization or American Diabetes Association
3. Presence of center-involving DME in the study eye with CST ≥ 325 μm
4. Visual acuity loss in the study eye attributed to DME with screening and baseline ETDRS BCVA letter score of 20 to 55 (20/400 to 20/80 Snellen equivalent) in the sentinel patients and 35 to 70 (20/200 to 20/40 Snellen equivalent) in the non-sentinel patients
5. Cohort 1: Previously treated with an anti-VEGF in the study eye; Cohorts 2, 3, and 4: Previously treated or treatment-naïve to the study eye

Exclusion Criteria

1. Uncontrolled diabetes mellitus, defined as hemoglobin A1c \> 12.0% at Screening
2. Uncontrolled hypertension with systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg at Screening or Baseline
3. Chronic renal disease
4. Any active infection in either eye
5. Any anti-vascular endothelial growth factor (VEGF) treatment in the study eye within 6 to 8 weeks prior to Baseline
6. Use of Ozurdex (dexamethasone) within 6 months prior to Baseline or any use of Iluvien (fluocinolone acetonide) in the study eye
7. Uncontrolled intraocular pressure (IOP), defined as an IOP \> 25 mmHg, despite anti-glaucoma medications in the study eye at the time of screening or controlled glaucoma that requires management with \> 2 topical hypotensive medications
8. Any anti-integrin therapy (e.g., Xiidra) within 60 days before baseline in the study eye

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No